NasdaqHealth CareHealth Care SuppliesS&P SmallCap 600
$87.23
-2.39 (-2.67%)
Close of Nov 06, 2026 · end-of-day data
MMSI 8-K filings in 2025
Every material Form 8-K Merit Medical Systems filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Merit Medical reported third-quarter 2025 revenue of $384.2 million, up 13.0%, and non-GAAP EPS of $0.92, up 6.7%, while GAAP EPS fell 3.0% to $0.46. The company raised its full-year 2025 net sales guidance to $1.502 to $1.515 billion and its non-GAAP EPS guidance to $3.66 to $3.79, and it said Martha G. Aronson has joined as President and CEO.
Q3 2025 revenue was $384.2 million, up 13.0% from $339.8 million a year earlier; constant currency revenue, organic, rose 7.8%
GAAP net income was $27.8 million, or $0.46 per diluted share, versus $28.4 million, or $0.48, in Q3 2024; non-GAAP EPS was $0.92 versus $0.86
Full-year 2025 net sales guidance rose to $1.502 to $1.515 billion from $1.495 to $1.507 billion; non-GAAP EPS guidance rose to $3.66 to $3.79 from $3.52 to $3.72
Martha G. Aronson is quoted as President and CEO, with the company referring to a transition from current leadership
Merit Medical Systems appointed Martha G. Aronson as President and CEO effective October 3, 2025, succeeding Fred P. Lampropoulos, who remains Chairman of the Board. The board also expanded its size from ten to eleven directors and added Ms. Aronson to the board, a leadership change that matters to shareholders as it sets a new chief executive direction.
Martha G. Aronson becomes President and CEO and a director effective October 3, 2025.
Fred P. Lampropoulos resigned as CEO and will serve as Executive Chairman until January 3, 2026, then remain a director and Chairman.
Ms. Aronson's offer letter includes a $1,000,000 base salary, a $250,000 signing bonus, and a target bonus of 100% of base salary.
Her initial equity award has a target grant date fair value of $5,500,000, and an upfront equity grant of $4,125,000 is planned.
Merit Medical reported second-quarter 2025 revenue of $382.5 million, up 13.2% from a year earlier, and raised its full-year 2025 net sales and non-GAAP earnings per share guidance. GAAP earnings per share fell to $0.54 from $0.61, while non-GAAP earnings per share rose to $1.01 from $0.92. The company also named Martha Aronson as its new President and Chief Executive Officer, effective October 3, 2025.
Q2 2025 net sales were $382.5 million, up 13.2%; constant currency revenue, organic, rose 6.7%
2025 net sales guidance raised to $1.495 billion to $1.507 billion from $1.480 billion to $1.501 billion
2025 non-GAAP EPS guidance raised to $3.52 to $3.72 from $3.28 to $3.41
Martha Aronson named President and CEO, effective October 3, 2025
Merit Medical said on July 7, 2025 that Martha Aronson will become President and CEO effective October 3, 2025, succeeding Fred Lampropoulos, who will remain Chairman. The company also reported preliminary, unaudited second-quarter revenue of approximately $380 million to $384 million, up about 12% to 14% from the prior-year quarter, with constant currency growth of about 11% to 13%. The revenue figures are not audited and may change when full results are released on July 30, 2025.
Martha Aronson to succeed Fred Lampropoulos as CEO effective October 3, 2025; Lampropoulos remains Chairman
Aronson offer includes a $1,000,000 base salary, a $250,000 signing bonus and a target annual bonus of 100% of salary
Initial equity award with a target grant-date fair value of $5,500,000, plus a $4,125,000 award on commencement of employment
Preliminary Q2 revenue of approximately $380 million to $384 million versus $338.0 million a year earlier; full results due after market close July 30, 2025
Merit Medical completed its merger with Biolife on May 20, 2025, paying about $120 million in cash on hand, and updated its 2025 guidance to include the business. Net sales guidance was raised to $1.480 billion to $1.501 billion from $1.470 billion to $1.490 billion, while the non-GAAP earnings per share range moved to $3.28 to $3.41 from $3.29 to $3.42. Management said the deal will be slightly dilutive to 2025 non-GAAP profitability.
Purchase price of about $120 million, subject to standard adjustments, paid with available cash; merger effective May 20, 2025
Biolife projected to contribute $10 million to $11 million of revenue from May 20 to December 31, 2025, after about $15 million in revenue for the twelve months ended December 31, 2024
2025 net sales guidance raised to $1.480 billion to $1.501 billion; non-GAAP EPS guidance $3.28 to $3.41 versus prior $3.29 to $3.42
About $7.2 million of non-cash and non-recurring transaction expenses excluded from non-GAAP projections; deal projected to be dilutive to 2025 GAAP net income and EPS
Merit Medical reported first-quarter 2025 revenue of $355.4 million, up 9.8%, and non-GAAP EPS of $0.86, up 14.8%. It kept its 2025 net sales guidance unchanged but lowered its 2025 non-GAAP EPS guidance, citing the projected impact of recently implemented trade policies, which matters to shareholders because it reduces expected full-year earnings even as first-quarter results beat expectations.
Q1 2025 net sales of $355.4 million, up 9.8% from $323.5 million a year earlier; GAAP net income of $30.1 million, or $0.49 per diluted share, versus $0.48 a year earlier
Non-GAAP EPS of $0.86 in Q1 2025, versus $0.75 in Q1 2024
2025 non-GAAP EPS guidance lowered to $3.29 to $3.42 from $3.58 to $3.70, citing trade policies
2025 net sales guidance reaffirmed at $1.470 billion to $1.490 billion
Merit Medical reported fourth-quarter and full-year 2024 results on February 25, 2025, with revenue up 9.4% in the quarter and 7.9% for the year. The company also issued 2025 guidance calling for revenue of $1.470 billion to $1.490 billion and non-GAAP earnings per share of $3.58 to $3.70, up 8% to 10% and 4% to 7% from 2024. GAAP earnings per share in the quarter slipped to $0.46 from $0.47 a year earlier.
Q4 2024 revenue was $355.2 million, up 9.4%; GAAP net income was $27.9 million, or $0.46 per diluted share, versus $0.47 a year earlier
Q4 2024 non-GAAP EPS was $0.93, up 25.8% from the prior year period
Full-year 2024 revenue was $1.357 billion, up 7.9%; GAAP EPS was $2.03 versus $1.62 in 2023
2025 guidance: revenue of $1.470 billion to $1.490 billion and non-GAAP EPS of $3.58 to $3.70
Merit Medical said preliminary unaudited revenue for the year ended December 31, 2024 is about $1.355 billion to $1.357 billion, up about 7.7% to 7.9% from the prior year. The figures are unaudited and may change after the audit, and the company plans to report full fourth-quarter and 2024 results and 2025 guidance on February 25, 2025.
Preliminary 2024 revenue of about $1.355 billion to $1.357 billion, up about 7.7% to 7.9% year over year
Preliminary constant currency revenue increased about 8.4% to 8.6%; the foreign exchange impact is $7.9 million
Audited results are not yet available, and the auditor has not reviewed the preliminary figures
Full 2024 results and fiscal 2025 guidance are scheduled for February 25, 2025 after market close
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Merit Medical Systems filing is on SEC EDGAR ↗. 8-K briefs of other companies →